MS4A1 and cancer: Furthermore, mAbs targeting pan-cancer antigens, such as rituximab (targeting CD20), trastuzumab (targeting HER2), and cetuximab (targeting EGFR), have been shown to rely on NK cell-mediated ADCC for their anti-tumor effects, though other immune cells including macrophages, dendritic cells, and granulocytes are also known to contribute (45–48).